# Cover Letter Template for ANZJP Manuscript Submission

[Your Name]  
[Your Academic Title]  
[Your Department]  
[Your Institution]  
[Your Address]  
[City, State, Postcode]  
[Country]  
Email: [your.email@institution.edu.au]  
Phone: [+61/country code] [your phone number]  
Date: [Submission Date]  

Editor-in-Chief  
Australian and New Zealand Journal of Psychiatry  
[Royal Australian and New Zealand College of Psychiatrists]  
[Address]  
[City, State, Postcode]  
[Country]  

Dear Editor-in-Chief,

## Manuscript Submission
I am pleased to submit our manuscript entitled "Cost-Effectiveness of Ketamine, Esketamine, and Psilocybin vs ECT for Treatment-Resistant Depression in Australia and New Zealand" for consideration for publication in the Australian and New Zealand Journal of Psychiatry.

## Manuscript Details
- **Type of Submission**: Original Research Article
- **Word Count**: 6,648 words (excluding abstract, references, tables, and figures)
- **Abstract Word Count**: 225 words
- **Number of Tables**: 4 in manuscript + 6 supplementary
- **Number of Figures**: 4 in manuscript + 10 supplementary
- **Number of References**: 20

## Key Findings
This manuscript presents the first comprehensive cost-effectiveness analysis comparing psychedelic therapies with electroconvulsive therapy for treatment-resistant depression in Australia and New Zealand.

Our key findings include:
- ECT remains the most cost-effective intervention in base-case analysis
- Intravenous ketamine showed ICERs of AUD $28,500/QALY and NZD $26,800/QALY
- Esketamine was not cost-effective at current prices (ICER AUD $156,000/QALY)
- Psilocybin had intermediate cost-effectiveness (ICER AUD $42,300/QALY)
- Probabilistic analysis showed 45% probability of ketamine cost-effectiveness in Australia at $50,000/QALY threshold

## Importance to Field
This work is important because it provides the first comprehensive economic evaluation of psychedelic therapies as alternatives to ECT in Australia and New Zealand, addressing a critical gap in the evidence base for treatment-resistant depression. The findings have direct implications for clinical practice and health policy in both countries, where ECT utilization has declined but psychedelic therapies are emerging as potential alternatives. Our analysis demonstrates that while ECT remains cost-effective, ketamine offers a viable option for non-psychotic TRD cases, supporting gradual integration of psychedelic therapies alongside ECT.

## Originality
To our knowledge, this is the first study to conduct a comprehensive cost-effectiveness analysis comparing intravenous ketamine, intranasal esketamine, and psilocybin-assisted therapy with electroconvulsive therapy in Australia and New Zealand. While previous studies have examined individual psychedelic therapies or conducted analyses in other countries, our study uniquely evaluates all three major psychedelic interventions against ECT using country-specific data, including local costs, reimbursement structures, and willingness-to-pay thresholds ($50,000/QALY for Australia and $45,000/QALY for New Zealand).

## Compliance with Journal Requirements
This manuscript:
- Follows the IMRAD structure (Introduction, Methods, Results, Discussion)
- Includes all required sections for ANZJP submissions
- Adheres to the journal's word limits and formatting guidelines
- Includes a comprehensive abstract (â‰¤250 words)
- Provides complete author information and declarations
- Includes all necessary supplementary materials

## Ethical Considerations
This study [describe ethical considerations, approvals, or why none were needed].

## Funding and Conflicts
[Brief statement about funding sources and conflicts of interest, if any].

## Suggested Reviewers
We suggest the following experts as potential reviewers:

1. [Name], [Title], [Institution], [Email] - Expertise in [area]
2. [Name], [Title], [Institution], [Email] - Expertise in [area]
3. [Name], [Title], [Institution], [Email] - Expertise in [area]

We also suggest excluding the following individuals due to [reason]:
- [Name], [Institution] - [Reason for exclusion]

## Previous Presentations
Portions of this work have been presented at:
- [Conference Name], [Location], [Date] - [Presentation format, e.g., poster/oral presentation]
- [Conference Name], [Location], [Date] - [Presentation format]

## Acknowledgments
We would like to acknowledge [brief acknowledgment of contributors, if not in manuscript].

## Submission Declaration
All authors have approved the manuscript and agree with its submission to the Australian and New Zealand Journal of Psychiatry. The manuscript has not been published previously and is not under consideration by another journal.

Thank you for considering our manuscript for publication. We look forward to your decision and are happy to provide any additional information required.

Sincerely,

[Your Full Name]  
[Your Academic Title]  
[Your Institution]  
[Your Contact Information]  

## Enclosures
- Manuscript file
- Title page with author details
- Figures and tables
- Supplementary materials
- [Any other required documents]

---

## Cover Letter Checklist
- [ ] Editor's name and address correct
- [ ] Manuscript title matches exactly
- [ ] Word count and statistics accurate
- [ ] Key findings clearly summarized
- [ ] Importance to field explained
- [ ] Originality stated
- [ ] Compliance with requirements confirmed
- [ ] Ethical considerations addressed
- [ ] Funding/conflicts declared
- [ ] Suggested reviewers provided
- [ ] Previous presentations listed
- [ ] All authors' approval confirmed
- [ ] No simultaneous submissions declared
- [ ] Professional and concise tone
- [ ] All enclosures listed